Flagship launches Ring with $50M, new gene therapy vectors

Ring aims to solve gene therapy’s biggest problems: immunogenicity, tissue access and genomic integration

Ring Therapeutics, the latest company to emerge from Flagship Pioneering, has a gene therapy platform that it thinks will solve the biggest problems with the modality: immunogenicity, tissue access and genomic integration.

With a $50 million initial investment, the company is creating a new type of viral vector based on a family of commensal human viruses dubbed anelloviruses, which naturally exist in most of the

Read the full 640 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers